Market Overview

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Share:
Related TEVA
Benzinga's Option Alert Recap From March 24
Teva's Stock Inches Higher Amid Cost-Cutting Plan
Biotech Forum Daily Digest: Obamacare To Stay? Flexion On The Block? Spotlight On Puma! (Seeking Alpha)

On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49.

Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”

Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”

Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.

Latest Ratings for TEVA

DateFirmActionFromTo
Feb 2017ArgusDowngradesHold
Feb 2017MizuhoDowngradesNeutralUnderperform
Jan 2017Bank of AmericaUpgradesNeutralBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Chris Schott JP MorganAnalyst Color Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!